50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1062% match
“Our mission is to develop therapies that empower the immune system to cure neurodegeneration and other diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2761% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0860% match
“Our mission is to commercialize innovative drug candidates with novel mechanisms of action as well as intellectual property generated from our research activities for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-07-1660% match
“Our mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-0159% match
“Our mission is to bring off-the-shelf cellular immunotherapies with disease-transforming potential initially to patients with autoimmune diseases and cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2659% match
“Our mission is to develop first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other rare disorders.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2759% match
“Our mission is to discover, develop, and deliver novel, life-transforming therapies to people suffering from rare, severe, and devastating neuromuscular diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0359% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1659% match
“Our mission is to cure genetic disease, overcome cancer, and feed the planet.”In use 2019 – now·1 sighting·SEC Form S-1/A, filed 2019-03-1359% match
“Our purpose is to develop and commercialize HSC gene therapies that free patients from a lifetime of genetic disease.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2359% match
“Our mission is to discover new medicines that improve the lives of people facing serious muscle disease.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2659% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2459% match
“Our mission is to liberate patients from autoimmune diseases through the curative potential of cell therapy.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2659% match
“Our purpose is to engage, directly or indirectly, in any lawful business activity or occupation whatsoever; provided, however, that we may donate reasonable amounts to worthy causes, as our board of directors may determine at its discretion, even if such donations are not within the framework of business considerations.”In use 2011 – now·1 sighting·SEC Form 20-F, filed 2011-06-1658% match
“Our mission is to one day end the suffering caused by neurodegenerative diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2258% match
“Our mission is to benefit patients by developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, with particular focus on orphan cancer indications.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-10-0758% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1458% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0158% match
“Our mission is to discover, develop and commercialize a new class of RNA editing therapies capable of improving the lives of patients with rare and highly prevalent diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1258% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2858% match
“Our purpose is to operate in accordance with business considerations to generate profits (provided, however, that we may donate reasonable amounts to worthy causes, as our board of directors may determine in its discretion, even if such donations are not within the framework of business considerations).”In use 2010 – now·1 sighting·SEC Form 20-F, filed 2010-03-2658% match
“Our mission is to expand our portfolio into a wide range of muscle diseases and become a leader in this area by advancing life-transforming therapeutics for patients with serious muscle diseases.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0458% match
“Our mission is to bring to market therapies that address high unmet medical needs of patients with genetic mitochondrial diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2758% match
“Our mission is to become the world leader in the sustainable manufacture of KLH and use our unique, proprietary methods and intellectual property to serve the growing demand for KLH in immunotherapeutic and immunodiagnostic markets.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-12-1457% match
“Our mission is to develop innovative therapies to address areas of high unmet medical need, initially in RASopathies for NF1.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3057% match
“Our mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2257% match
“Our mission is to transform the lives of patients living with devastating genetic diseases by building the leading integrated genetic medicine company focused on developing and commercializing potentially curative therapeutics based on our GeneRide platform.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-1557% match
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-07-3157% match
“Our mission is to improve the quality of life of people suffering from cancer and to increase shareholder value by commercializing our platform technologies through in-house development, joint ventures, strategic alliances and licensing arrangements.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-07-2957% match
“Our mission is to leverage our unique insights into finding and binding cryptic functional pockets on currently intractable human biology-validated protein targets to discover, develop and commercialize small molecule therapies that can transform the lives of patients suffering from devastating cancers and immune disorders.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-06-2557% match
“Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1057% match
RPRelx PlcCompany · Professional services · X0 Real “Our purpose is to benefit society by developing products that help researchers advance scientific knowledge; doctors and nurses improve the lives of patients; lawyers promote the rule of law and achieve justice andfair results for their clients; businesses and governments prevent fraud; consumers access financial services and get fair prices on insurance; and customers learn about markets and complete transactions.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-02-1957% match
“Our mission is to create long-term stockholder value by acquiring, developing and commercializing innovative products for the treatment of a variety of human diseases that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment.”In use 2014 – now·1 sighting·SEC Form 10-K, filed 2014-03-1157% match
“Our mission is to solve unmet medical needs by commercializing discoveries from research universities and medical centers We are a biopharmaceutical company that seeks to bridge the “bench-to-bedside” gap between medical research discoveries and patient solutions.”In use 2022 – now·1 sighting·SEC Form S-1/A, filed 2022-04-1157% match
“Our mission is to develop and commercialize novel therapeutics to treat diseases of the eye, with an initial focus on diseases of the back of the eye.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-2157% match
“Our mission is to develop novel treatments for dormant cancers: targeting cancer resistance, metastasis, and relapse.”In use 2022 – now·1 sighting·SEC Form S-1/A, filed 2022-12-0856% match
“Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1256% match
“Our mission is to develop life-changing genetic medicines for people and their families impacted by devastating neurological diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2456% match
“Our mission is to develop therapeutic drugs designed to treat neurodegenerative diseases, currently focusing on Parkinsonian and other movement disorders.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-08-2856% match
“Our mission is to become a leading pharmaceutical company by pioneering Bicycle molecules as a novel therapeutic modality to treat diseases that are inadequately addressed with existing treatment modalities.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1756% match
“Our mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2756% match
“Our mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-2356% match
“Our mission is to both extend the functional life of transplanted organ and reduce side effect of current immunosuppressive treatments such as kidney toxicity, high blood pressure, and tremor.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1956% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1156% match
“Our mission is to provide therapeutic relief to those suffering from debilitating rare diseases that have limited or no treatment options to help them live their best possible lives and achieve their full potential.”In use 2024 – now·1 sighting·SEC Form 20-F, filed 2024-04-3056% match
“Our mission is to discover and develop novel therapeutics to improve the lives of patients living with debilitating CNS disorders.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-10-0656% match
“Our mission is to discover and develop effective biologic treatments applicable to a range of challenging, validated targets with high potential to help people with life-threatening conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1956% match
“Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biopharmaceutical company with a differentiated and sustainable product portfolio by focusing on the following:.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2856% match
“Our mission is to harness the power of the immune system to improve lives and eradicate cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1256% match
Showing 1–50 of 50